Navigation Links
Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Date:1/28/2009

MONTVALE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) today announced that, following a review of its clinical development portfolio and its current financial status, the Board of Directors and management have determined that it is in the best interest of the Company to focus its resources on maximizing the value of its diagnostic assets and to terminate all ongoing clinical trials of its product candidates alagebrium and SYI-2074, including the following:

- the BENEFICIAL study, which was a Phase 2 double-blind, placebo-controlled, randomized trial of alagebrium in patients with chronic systolic heart failure;

- the BREAK study, which was a Phase 2 double-blind, placebo-controlled, randomized trial of alagebrium in patients with diastolic heart failure; and

- the Phase 2 trial of a topical formulation of SYI-2074 for the treatment of chronic, mild-to-moderate plaque psoriasis in adults.

Each of these trials will be terminated as promptly as possible.

As noted previously, the Company has submitted an application for 510(k) clearance for its HAPTOCHEK(TM) diagnostic test kit, a protein-based clinical laboratory test to identify patients with Hp2-2 diabetes. The 90-day review process of such submission is ongoing, during which time the FDA will determine whether the kit can be distributed to labs throughout the country as an in vitro diagnostic.

The Company is continuing to explore strategic alternatives in order to monetize its technology assets, which may take the form of sales or licensing transactions with respect to those assets. In light of the Company's cash position and current negative economic and capital markets conditions, if the Company is unable to enter into such transactions in a timely manner, the Company's ability to continue operations beyond the second quarter of 2009 is in do
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
3. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
4. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
5. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
6. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
7. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
8. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
9. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
10. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... 47.54 billion by 2020, according to a new study by Grand ... II diabetes and the presence of high unmet needs in emerging ... China are expected to be two of the most ... lifestyle induced diseases such as obesity and growing global geriatric population ...
(Date:6/29/2015)... CITY, Mo. , June 29, 2015  Missouri ... the 2015 first quarter data from the state,s real-time, ... (NPLEx). States across the United ... Missouri one of 31 across the country ... attempted pseudoephedrine (PSE) purchases at the point of sale.  ...
(Date:6/29/2015)... KING OF PRUSSIA, Pa. , June 29, 2015 ... Alsharabati, MD, University of Alabama at Birmingham, ... 2015 Interlaken Leadership Award for ... global awards program provides monetary grants and/or product supply ... potential role of immunoglobulin (Ig) therapy in the treatment ...
Breaking Medicine Technology:Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 2CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 3
... 5, 2011 In its April issue, published this ... magazine has announced the winners of the fourteenth annual ... (Logo:  https://photos.prnewswire.com/prnh/20101214/LA16070LOGO) Sponsored by MD+DI ... the premier awards program for the medical technology community. ...
... April 5, 2011 RESMED INC. (NYSE: RMD ... will release its results for the third quarter and nine ... press release with ResMed,s results will be issued after 1:00 ... call and webcast to review its results, market trends, and ...
Cached Medicine Technology:37 Innovative Products Win Medical Design Excellence Awards 237 Innovative Products Win Medical Design Excellence Awards 337 Innovative Products Win Medical Design Excellence Awards 4ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:6/30/2015)... ... 30, 2015 , ... The American Psychiatric Nurses Association ... Coronado Springs Resort in Lake Buena Vista, Florida, and will offer more than ... for psychiatric-mental health nursing draws more than 1,500 health care professionals from around ...
(Date:6/30/2015)... ... 30, 2015 , ... This Fourth of July, Peacock Alley celebrates ... hard work, tenacity, perseverance, commitment to quality, honesty and love of friends and family. ... Ella Gabler's simple love of quilts, Peacock Alley was fully realized and grown while ...
(Date:6/29/2015)... ... , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame Oil ... skincare and even culinary uses, was especially designed for Oil Pulling. , To ... Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy and ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in Utah Valley ... much-needed autism support center, planned at Utah Valley University, in Orem, Utah. The ... center and the building in which it will be housed. , Utah Valley has ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... spine surgeon, Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team ... locations including Long Beach , Irwindale and La Tijera-Los Angeles. , ...
Breaking Medicine News(10 mins):Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 2Health News:American Psychiatric Nurses Association 29th Annual Conference: Continuing Education and Collaboration in Psychiatric-Mental Health and Nursing 3Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3
... Data published in the June issue of the ... biospectroscopy was able to identify changes in oxidative stress ... be a useful biomarker in the early detection of ... for diagnosing Alzheimer,s disease. Researchers at McGill University ...
... June 12, 2009 -- The Association for Molecular ... letter it has provided to the Federal Coordinating Council ... forth its recommendations for priority areas on which to ... in Congress and among other policy makers who see ...
... June 16 The U.S. Food and Drug Administration (FDA) ... draft guidance for the food industry, developed in response to ... of 2007 (Pub. L.110-085). The RFR is scheduled for implementation ... of foods, including dietary supplements. Only infant formula is exempt ...
... is a clinically proven, anti-aging beauty infusion that greatly improves ... nails . In comprehensive multicenter clinical trials, 86% of ... within 3 weeks*! , , To view the Multimedia ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090616/NY32948 ) , ...
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory have demonstrated ... developed into a method for early diagnosis of Alzheimer,s disease. ... in breast tissue and cartilage in human knee and ankle ... ability to visualize a class of miniscule plaques that are ...
... the Addiction Treatment Gap (CATG) Poll Shows Widespread Concern about ... June 16 A new poll conducted for ... regardless of race, age, where people live or income, most ... or drugs, are worried about access to affordable treatment and ...
Cached Medicine News:Health News:New data demonstrate potential for early detection of Alzheimer's disease 2Health News:AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research 2Health News:AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research 3Health News:Reportable Food Registry Draft Guidance Published for Comment by FDA 2Health News:Video: 'BeautyScoop(R) Is a Trip to Your Nutritionist and Dermatologist in One Single Packet.' Lauren Slayton, NYC Nutritionist & Owner of FoodTrainers 2Health News:X-rays for early Alzheimer's disease detection 2Health News:X-rays for early Alzheimer's disease detection 3Health News:New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform; All Demographics Report Personal Experience With the Disease 2Health News:New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform; All Demographics Report Personal Experience With the Disease 3Health News:New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform; All Demographics Report Personal Experience With the Disease 4
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Rochester Medical's line of ... intermittent catheters you would ... four product configurations - ... antibacterial hydro - are ...
... The Mentor Freedom Pak Seven ... packaged week's supply of Freedom ... kit all 100% latex-free ... wipes for your convenience and ...
Medicine Products: